FDA Approved: KRINTAFEL — Original Application (GlaxoSmithKline LLC)

View source ↗

Summary

FDA approves Krintafel (tafenoquine succinate) from GlaxoSmithKline LLC through an original application for the radical cure of Plasmodium vivax malaria.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plasmodium Vivax Malaria

Drugs mentioned

• KRINTAFEL (tafenoquine succinate)

Snippet

ORIG AP for KRINTAFEL (TAFENOQUINE SUCCINATE)